Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 70436-012; 70436-013; 50090-4806; 0054-0401; 46708-152; 70518-3195; 68382-469; 0591-3659; 71335-1815; 0054-0603; 70436-036; 71335-1753; 51407-023; 0591-4060; 50090-4388; 63304-191; 0591-3660; 14501-0068; 46708-153; 60687-607; 70771-1311; 68382-741; 71335-1975; 0054-0400; 51407-022; 63304-192; 63629-7524; 71335-1700; 70771-1312; 69766-025
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams17.15.02.001; 19.02.03.0010.003807%Not Available
Aggression19.05.01.0010.003384%Not Available
Agitation19.06.02.001; 17.02.05.0120.009729%
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.0010.003384%
Amnesia19.20.01.001; 17.03.02.0010.003807%
Anaemia01.03.02.001--
Anger19.04.02.0010.005499%Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Angle closure glaucoma06.03.01.001--Not Available
Anorgasmia19.08.01.0010.000846%
Anxiety19.06.02.0020.014804%
Apathy19.04.04.0020.000846%Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthropathy15.01.01.0030.000846%Not Available
Asthenia08.01.01.0010.006768%Not Available
Back pain15.03.04.005--
Blindness17.17.01.003; 06.02.02.0010.000846%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood cholesterol13.12.01.014--Not Available
Blood cholesterol increased13.12.01.0020.001692%
Blood glucose increased13.02.02.0020.001269%Not Available
Blood pressure increased13.14.03.0050.008883%Not Available
Blood prolactin increased13.10.03.0020.000846%Not Available
Blood triglycerides13.12.03.004--Not Available
Blood triglycerides increased13.12.03.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 11 Pages